Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.72B | 849.59M | 612.87M | 388.62M | 118.44M |
| Total Depreciation and Amortization | 55.43M | 54.76M | 54.81M | 55.66M | 56.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.38B | 585.36M | 570.70M | 524.58M | 571.03M |
| Change in Net Operating Assets | -502.31M | -632.07M | -577.65M | -498.96M | -534.10M |
| Cash from Operations | 901.77M | 857.64M | 660.72M | 469.91M | 211.69M |
| Capital Expenditure | -149.64M | -91.95M | -71.56M | -58.70M | -44.50M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -588.27M | 166.89M | 368.58M | 495.03M | 465.08M |
| Cash from Investing | -737.90M | 74.94M | 297.02M | 436.33M | 420.59M |
| Total Debt Issued | -680.00K | 645.69M | 645.69M | 645.69M | 646.37M |
| Total Debt Repaid | -52.25M | -1.19B | -1.19B | -1.19B | -1.14B |
| Issuance of Common Stock | 103.88M | 166.16M | 213.82M | 250.03M | 244.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 64.67M | 57.96M | 51.74M | 45.90M | -15.93M |
| Cash from Financing | 115.62M | -322.83M | -281.38M | -251.02M | -265.34M |
| Foreign Exchange rate Adjustments | -16.47M | -16.14M | 13.81M | 34.94M | 23.37M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 263.02M | 593.62M | 690.17M | 690.16M | 390.30M |